ReviewCurrent treatment options in oncology2002
Primary pericardial mesothelioma.
Review in Current treatment options in oncology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases.Cancer reports (Hoboken, N.J.) · 2026Article
- Diagnosis and treatment of cardiac tumors.Medical oncology (Northwood, London, England) · 2025Review
- Long-term survival from multidisciplinary treatment of primary malignant pericardial mesothelioma: A case report.International journal of surgery case reports · 2024Article
- Multiple serous membrane effusion caused by primary pericardial mesothelioma.Radiology case reports · 2023Article
- Case Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history.Frontiers in cardiovascular medicine · 2023Article
- Cardiac Tumors:JACC. CardioOncology · 2020Review
- A Malignant Case of Constrictive Pericarditis.CASE (Philadelphia, Pa.) · 2017Article
- Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.Oncology letters · 2016Article
- Successful palliation for an aged patient with primary pericardial mesothelioma.World journal of surgical oncology · 2015Article
- MRI assessment of cardiac tumours: part 2, spectrum of appearances of histologically malignant lesions and tumour mimics.Quantitative imaging in medicine and surgery · 2014Review
- Three-year survival after surgery for primary malignant pericardial mesothelioma: report of a case.Surgery today · 2014Article
- A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction.BMJ case reports · 2014Article
- Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?Frontiers in genetics · 2014Article
- A Ball in the Heart: An Interesting Discovery in a Very RareCardiac Tumor.Journal of cardiovascular and thoracic research · 2013Article
- Primary pericardial mesothelioma: a rare entity.Case reports in oncological medicine · 2013Article
- False aneurysm of ascending aorta due to pericardial mesothelioma.Interactive cardiovascular and thoracic surgery · 2012Article
- A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.Rare tumors · 2012Article
- Article
- Surprising finding of a primary pericardial mesothelioma.The international journal of cardiovascular imaging · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pericardial mesothelioma is a rare cancer for which treatment options are limited. Operative intervention in pericardial mesothelioma is primarily for effusion control, for cytoreduction before multimodal therapy, or to deliver and monitor innovative intrapericardial therapies. Misdiagnosis is common. Early detection of the disease is the only hope for survival. Echocardiography, pathologic examination of pericardial fluid and pericardial biopsy, Gallium-67 scintigraph, Ber-EP4 antibody, and immunohistochemical procedures can be used. Magnetic resonance imaging is emerging as the best modality for demonstrating the nature and extent of the constrictive process, and the infiltration to the cardiac wall and great vessels. Failure of surgical techniques is usually associated with mesothelioma with entrapped heart, a large solid tumor mass, and a long history of pericardial effusion. If the tumor is localized, resection is the only hope for this rare, but lethal, entity. No single treatment modality is efficient by itself. The exact role of intracavitary chemotherapy or irradiation remains to be defined. Preliminary clinical application of photodynamic therapy and attempts at inhibiting the effects of growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, and vaccine treatments are being explored. Adenoviral molecular chemotherapy recently completed phase I testing. Clinical trials for pleural mesothelioma remain important as clinicians seek to improve the outcome for patients with pericardial mesothelioma. Early diagnosis and multidisciplinary patient care is essential for improved surgical outcome. In the future, combined therapeutic strategies involving radical surgery, radiotherapy, adjuvant chemotherapy, and immunomodulation may have a role in the treatment of pericardial mesotheliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.